Exicure to Present at the Chardan Virtual 5th Annual Genetic Medicines Conference

Rhea-AI Summary

Exicure (NASDAQ: XCUR), a leader in gene regulatory drugs, will present at the Chardan Virtual 5th Annual Genetic Medicines Conference on October 5, 2021, from 11:00 AM to 11:25 AM ET. Attendees can access the presentation via a live webcast. The session will also be available for replay for 30 days afterward. Exicure is focused on therapeutics for various diseases, including Friedreich’s ataxia and advanced solid tumors, leveraging its proprietary Spherical Nucleic Acid technology.

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Exicure, Inc.^® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced a presentation at the Chardan Virtual 5th Annual Genetic Medicines Conference on Tuesday, October 5, 2021.

Date: Tuesday, October 5, 2021
Time: 11:00 – 11:25 AM Eastern Time
Location: Virtual Webcast

The presentation will be available for live streaming via https://wsw.com/webcast/chard9/xcur/1885590

Replays of the webcast will be available on Exicure’s website for 30 days following the webcast.

About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on its proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure is in preclinical development of XCUR-FXN a lipid-nanoparticle SNA–based therapeutic candidate, for the intrathecal treatment of Friedreich’s ataxia (FA). Exicure’s therapeutic candidate cavrotolimod (AST-008) is in a Phase 1b/2 clinical trial in patients with advanced solid tumors. Exicure is based in Chicago, IL and in Cambridge, MA. www.exicuretx.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20211004005987/en/

Karen Sharma

MacDougall

781-235-3060

ksharma@macbiocom.com

Source: Exicure, Inc.

FAQ

What is Exicure's stock symbol?

Exicure's stock symbol is XCUR.

When is Exicure's presentation at the Genetic Medicines Conference?

Exicure's presentation is scheduled for October 5, 2021, from 11:00 AM to 11:25 AM ET.

How can I watch Exicure's presentation?

You can watch Exicure's presentation via a live webcast.

What is the focus of Exicure's research?

Exicure focuses on therapeutics for neurology, immuno-oncology, and other genetic disorders using Spherical Nucleic Acid technology.

What is the potential use of Exicure's XCUR-FXN candidate?

XCUR-FXN is being developed for the intrathecal treatment of Friedreich's ataxia.